0

Eric Pujade Lauraine

Paris Descartes University, France

Presentation Title:

Innovative Academic Homologous Recombination Deficiency (HRD) Tests in Advanced Ovarian Cancer: The European Initiative

Abstract

Recently the PAOLA-1/ENGOT-ov25 phase-3 study (Ray-Coquard Ann Oncol 2023) showed that the addition of olaparib maintenance to 1st-line platinum-based therapy and bevacizumab improved survival of Advanced Ovarian Cancer (AOC) patients with HRD positive tumors independently of BRCA status (Myriad myChoice test). The aim of this unique European ENGOT initiative was to validate novel academic HRD assays on >350 PAOLA-1 tumor samples whose results were correlated with PAOLA-1 clinical survival data and Myriad test results. A total of 8 tests were clinically validated. The results of these novel HRD tests did not differ significantly from Myriad test results. Progression-free survival hazard ratio between Olaparib and placebo arms depending on the assay was between 0.30 and 0.50 for HRD-positive patients and between 0.88 and 1.15 for HRD-negative patients. This unique European initiative allowed to validation of 8 novel HRD tests available to select PARP inhibitor maintenance treatment for ovarian cancer patients. 

Biography

Eric Pujade-Lauraine is a Professor emeritus of Medical Oncology at the Paris Descartes University (Paris V). He is the founding member of the French Group of National Investigators of the studies on Gynecological Cancers (GINECO), a group devoted to clinical research in gynaecological cancer and labelled by the French Cancer Institute (INCA). Professor Pujade-Lauraine is currently Medical Director of the GINECO operational structure (ARCAGY) and has served as a member of the US National Cancer Institute Gynaecologic Cancer Steering Committee and as Chair of the nIternational Gynecologic Cancer Intergroup (GCIG), Chair and founder of the European Gynaecologic Cancer Academy and the European translational research working group. Professor Pujade-Lauraine is a co-author to more than 250 peer-reviewed articles including some landmark practice-changing trials in gynecological cancer and particularly in ovarian cancer.